Campbell C C, Payne D, Schwartz I K, Khatib O J
Am J Trop Med Hyg. 1983 Nov;32(6):1216-20. doi: 10.4269/ajtmh.1983.32.1216.
Amodiaquine, a 4-aminoquinoline which has been shown to be effective in treating infections with chloroquine-resistant strains of Plasmodium falciparum, was evaluated against chloroquine-resistant infections in children in Zanzibar, Tanzania, during July 1982. A 25-mg base/kg dosage of amodiaquine produced parasite clearance in 34 of 38 (89%) children in a mean of 2.8 days. When followed for 28 days, 15 of 38 (39%) children were completely cured of their infection as judged by the absence of renewed parasitemia. The parasite clearance rates produced by amodiaquine were significantly higher than those observed in a comparison group of children treated with 25 mg base/kg chloroquine. There was, however, no difference in the cure rates in the chloroquine and amodiaquine groups. Despite the enhanced parasite clearance rate, amodiaquine is not sufficiently more effective against Zanzibari strains of P. falciparum to replace chloroquine. Other alternative drugs must be evaluated to define the optimal malaria therapy regimen on Zanzibar.
阿莫地喹是一种4-氨基喹啉,已证明对治疗耐氯喹恶性疟原虫感染有效。1982年7月,在坦桑尼亚桑给巴尔对儿童耐氯喹感染进行了该药的评估。25毫克碱基/千克剂量的阿莫地喹使38名儿童中的34名(89%)平均在2.8天内实现了寄生虫清除。在随后的28天观察期内,根据无寄生虫血症复发判断,38名儿童中有15名(39%)感染完全治愈。阿莫地喹产生的寄生虫清除率显著高于接受25毫克碱基/千克氯喹治疗的儿童对照组。然而,氯喹组和阿莫地喹组的治愈率没有差异。尽管寄生虫清除率有所提高,但阿莫地喹对桑给巴尔恶性疟原虫菌株的疗效提高程度不足以取代氯喹。必须评估其他替代药物,以确定桑给巴尔最佳的疟疾治疗方案。